Aug 24, 2023CCSS Response to Congressional Request for Information Regarding FDA Regulation of CBDCCSS has submitted comments in response to the Congressional RFI on FDA regulation of CBD products in the marketplace. The key topics...
Feb 3, 2023CCSS Statement on FDA Cannabinoid Pathway Framework AnnouncementCCSS looks forward to working with Congress and FDA on a science-based approach to regulate non-drug CBD products, protecting consumer...
Nov 14, 2022The Status and Risks of Unregulated Cannabinoid Products in the MarketplaceThe cannabis plant contains more than a hundred chemical compounds known as cannabinoids, including the more commonly known cannabidiol...